Disposition of 125000 shares by Jack Khattar of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3

Read at macroaxis.com

Published over a month ago View all stories for Aryx Therapeutics | Aryx Therapeutics Hype Analysis

Disposition of 125000 employee stock option (right to buy) at 9.13 of Supernus Pharmaceuticals by Jack Khattar on 7th of November 2024. This event was filed by Supernus Pharmaceuticals with SEC on 2024-11-07. Statement of changes in beneficial ownership - SEC Form 4. Jack Khattar currently serves as founder, ceo and president and director of Supernus Pharmaceuticals

We analyze Aryx Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aryx Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics with similar companies.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.